MacroGenics, Inc. - Common Stock (NQ:MGNX)

2.315 -0.065 (-2.73%)

Delayed Quote Updated: 9:46 AM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MacroGenics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Shareholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against MacroGenics, Inc. (MGNX)

July 30, 2024

From Robbins LLP

Via GlobeNewswire

MACROGENICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against MacroGenics, Inc. and Encourages Investors to Contact the Firm

July 30, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

MACROGENICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against MacroGenics, Inc. - MGNX

July 30, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

Expert Outlook: Macrogenics Through The Eyes Of 7 Analysts ↗

July 29, 2024

Via Benzinga

Demystifying Macrogenics: Insights From 14 Analyst Reviews ↗

May 24, 2024

Via Benzinga

MacroGenics Provides Vobramitamab Duocarmazine Update

July 30, 2024

From MacroGenics, Inc.

Via GlobeNewswire

MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte

July 30, 2024

Confirming cash runway guidance into 2026

From MacroGenics, Inc.

Via GlobeNewswire

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of MacroGenics, Inc. (MGNX) Investors

July 30, 2024

From Kirby McInerney LLP

Via Business Wire

MGNX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces That MacroGenics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 30, 2024

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 29, 2024

From The Schall Law Firm

Via Business Wire

MACROGENICS, INC. (NASDAQ: MGNX) INVESTOR ALERT: Investors With Large Losses in MacroGenics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

July 29, 2024

From Bernstein Liebhard LLP

Via GlobeNewswire

Rosen Law Firm Urges MacroGenics, Inc. (NASDAQ: MGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

July 29, 2024

From The Rosen Law Firm, P.A.

Via Business Wire

DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 26, 2024

Via Benzinga

MacroGenics to Participate in Upcoming Investor Conference

June 11, 2024

From MacroGenics, Inc.

Via GlobeNewswire

3 Biotech Stocks That Could Be Millionaire-Makers: May Edition ↗

May 25, 2024

Investors should take a close look at these biotech stocks as they position themselves to provide high returns.

Via InvestorPlace

Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 03, 2024

Via Benzinga

MACROGENICS ALERT: Bragar Eagel & Squire, P.C. is Investigating MacroGenics, Inc. on Behalf of MacroGenics Stockholders and Encourages Investors to Contact the Firm

May 14, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against MacroGenics, Inc. (MGNX)

May 13, 2024

From Kirby McInerney LLP

Via Business Wire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 13, 2024

Via Benzinga

MacroGenics to Participate in Upcoming Investor Conferences

May 13, 2024

From MacroGenics, Inc.

Via GlobeNewswire

Masters In Trading - Saturday, May 11 ↗

May 11, 2024

In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week.

Via Talk Markets

MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths' ↗

May 10, 2024

Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.

Via Benzinga

Crude Oil Down 1%; Sweetgreen Shares Spike Higher ↗

May 10, 2024

Via Benzinga

Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday? ↗

May 10, 2024

A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures.

Via Benzinga

Topics Economy

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 10, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 10, 2024

Via Benzinga

Nasdaq Moves Lower; US Consumer Sentiment Falls In May ↗

May 10, 2024

Via Benzinga

MacroGenics Shares Tumble After Reporting Adverse Events, Multiple Deaths In Cancer Drug Trial ↗

May 10, 2024

Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 in metastatic prostate cancer. Despite responses, notable safety concerns...

Via Benzinga

Topics Death

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm

May 10, 2024

From Schall Law

Via GlobeNewswire

Dow Jumps Over 100 Points; DNOW Posts Downbeat Earnings ↗

May 10, 2024

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.